|
1
|
Gresele P, Momi S and Falcinelli E:
Anti-platelet therapy: Phosphodiesterase inhibitors. Br J Clin
Pharmacol. 72:634–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomé MP, Pereira LC, Onzi GR, Rohden F,
Ilha M, Guma FT, Wink MR and Lenz G: Dipyridamole impairs
autophagic flux and exerts antiproliferative activity on prostate
cancer cells. Exp Cell Res. 382:1114562019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kohnoe S, Maehara Y, Takahashi I, Emi Y,
Baba H and Sugimachi K: Treatment of advanced gastric cancer with
5-fluorouracil and cisplatin in combination with dipyridamole. Int
J Oncol. 13:1203–1206. 1998.PubMed/NCBI
|
|
4
|
Rodrigues M, Barbosa F Jr and Perussi JR:
Dipyridamole increases the cytotoxicity of cisplatin in human
larynx cancer cells in vitro. Braz J Med Biol Res. 37:591–599.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kennedy DG, Van den Berg HW, Clarke R and
Murphy RF: Enhancement of methotrexate cytotoxicity towards the
MDA.MB.436 human breast cancer cell line by dipyridamole. The role
of methotrexate polyglutamates. Biochem Pharmacol. 35:3053–3056.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Mouwerik TJ, Pangallo CA, Willson JK
and Fischer PH: Augmentation of methotrexate cytotoxicity in human
colon cancer cells achieved through inhibition of thymidine salvage
by dipyridamole. Biochem Pharmacol. 36:809–814. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spano D, Marshall JC, Marino N, De Martino
D, Romano A, Scoppettuolo MN, Bello AM, Di Dato V, Navas L, De Vita
G, et al: Dipyridamole prevents triple-negative breast-cancer
progression. Clin Exp Metastasis. 30:47–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ge SM, Zhan DL, Zhang SH, Song LQ and Han
WW: Reverse screening approach to identify potential anti-cancer
targets of dipyridamole. Am J Transl Res. 8:5187–5198.
2016.PubMed/NCBI
|
|
9
|
Sakamoto KM and Frank DA: CREB in the
pathophysiology of cancer: Implications for targeting transcription
factors for cancer therapy. Clin Cancer Res. 15:2583–2587. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crans HN and Sakamoto KM: Transcription
factors and translocations in lymphoid and myeloid leukemia.
Leukemia. 15:313–331. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seo H, Liu DD, Bekele BN, Kim MK, Pisters
K, Lippman SM, Wistuba II and Koo JS: CREB Overexpression: A
Feature Associated with Negative Prognosis in Never-Smokers with
NSCLC. Cancer Res. 68:6065–6073. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shaywitz AJ and Greenberg ME: CREB: A
stimulus-induced transcription factor activated by a diverse array
of extracellular signals. Annu Rev Biochem. 68:821–861. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fajardo AM, Piazza GA and Tinsley HN: The
role of cyclic nucleotide signaling pathways in cancer: Targets for
prevention and treatment. Cancers (Basel). 6:436–458. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brunyanszki A, Olah G, Coletta C, Szczesny
B and Szabo C: Regulation of mitochondrial poly(ADP-Ribose)
polymerase activation by the β-adrenoceptor/cAMP/protein kinase A
axis during oxidative stress. Mol Pharmacol. 86:450–462. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Vos M, Schreiber V and Dantzer F: The
diverse roles and clinical relevance of PARPs in DNA damage repair:
Current state of the art. Biochem Pharmacol. 84:137–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Addioui A, Belounis A, Cournoyer S,
Nyalendo C, Brito RM, Beaunoyer M, Teira P and Sartelet H:
Preclinical study of a PARP inhibitor in neuroblastoma. J Clin
Oncol. 30 (Suppl 15):95702012. View Article : Google Scholar
|
|
17
|
Brenner JC, Feng FY, Han S, Patel S, Goyal
SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, et
al: PARP-1 inhibition as a targeted strategy to treat Ewing's
sarcoma. Cancer Res. 72:1608–1613. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zaremba T, Thomas H, Cole M, Plummer ER
and Curtin NJ: Doxorubicin-induced suppression of poly(ADP-ribose)
polymerase-1 (PARP-1) activity and expression and its implication
for PARP inhibitors in clinical trials. Cancer Chemother Pharmacol.
66:807–812. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan C, Luo L, Guo CY, Goto S, Urata Y,
Shao JH and Li TS: Doxorubicin-induced mitophagy contributes to
drug resistance in cancer stem cells from HCT8 human colorectal
cancer cells. Cancer Lett. 388:34–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kibria G, Hatakeyama H, Akiyama K, Hida K
and Harashima H: Comparative study of the sensitivities of cancer
cells to doxorubicin, and relationships between the effect of the
drug-efflux pump P-gp. Biol Pharm Bull. 37:1926–1935. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan C, Luo L, Goto S, Urata Y, Guo CY, Doi
H, Kitazato K and Li TS: Enhanced autophagy in colorectal cancer
stem cells does not contribute to radio-resistance. Oncotarget.
7:45112–45121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Omori K and Kotera J: Overview of PDEs and
their regulation. Circ Res. 100:309–327. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klijn C, Durinck S, Stawiski EW, Haverty
PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, et al: A
comprehensive transcriptional portrait of human cancer cell lines.
Nat Biotechnol. 33:306–312. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong JC, Bathina M and Fiscus RR: Cyclic
GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes
CREB phosphorylation and maintains higher c-IAP1, livin, survivin,
and Mcl-1 expression and the inhibition of PKG-Iα kinase activity
synergizes with cisplatin in non-small cell lung cancer cells. J
Cell Biochem. 113:3587–3598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ragazzi E, Berti E, Chiodo R, Dancona S
and Berti T: Dipyridamole as a modulator of multidrug-resistance in
tumor-cells in-vitro. Int J Oncol. 6:659–662. 1995.PubMed/NCBI
|
|
26
|
Weinländer G, Kornek G, Raderer M, Hejna
M, Tetzner C and Scheithauer W: Treatment of advanced colorectal
cancer with doxorubicin combined with two potential
multidrug-resistance-reversing agents: High-dose oral tamoxifen and
dexverapamil. J Cancer Res Clin Oncol. 123:452–455. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krishan A, Sridhar KS, Mou C, Stein WD,
Lyubimov E, Hu YP and Fernandez H: Synergistic effect of
prochlorperazine and dipyridamole on the cellular retention and
cytotoxicity of doxorubicin. Clin Cancer Res. 6:1508–1517, 2,000.
PubMed/NCBI
|
|
28
|
Wessler JD, Grip LT, Mendell J and
Giugliano RP: The P-glycoprotein transport system and
cardiovascular drugs. J Am Coll Cardiol. 61:2495–2502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nelson JA and Drake S: Potentiation of
methotrexate toxicity by dipyridamole. Cancer Res. 44:2493–2496.
1984.PubMed/NCBI
|
|
30
|
Solomon EI, Augustine AJ and Yoon J:
O2 reduction to H2O by the multicopper
oxidases. Dalton Trans. 30:3921–3932. 2008. View Article : Google Scholar
|
